Selected article for: "activation lead and lung inflammation"
Author: Sadikot, Ruxana T.; Kolanjiyil, Arun V.; Kleinstreuer, Clement; Rubinstein, Israel
Title: Nanomedicine for Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
  • Document date: 2017_6_27
    • ID: 27gutwjd_7
    Snippet: Thus, we have proposed innovative approaches that involve: (1) using GLP-1 peptides as an anti-inflammatory target; (2) targeting upstream molecules such as TREM1 [23, 24] and reactive oxygen species and Hsp90 that lead to activation of NF-κB, ultimately leading to ALI and ARDS, with poor outcomes in many cases (Fig. 1) ; and (3) developing a novel approach to deliver inhibitors of these molecules in vivo. We have shown that the individual nanof.....
    Document: Thus, we have proposed innovative approaches that involve: (1) using GLP-1 peptides as an anti-inflammatory target; (2) targeting upstream molecules such as TREM1 [23, 24] and reactive oxygen species and Hsp90 that lead to activation of NF-κB, ultimately leading to ALI and ARDS, with poor outcomes in many cases (Fig. 1) ; and (3) developing a novel approach to deliver inhibitors of these molecules in vivo. We have shown that the individual nanoformulations are effective at attenuating lung inflammation in a murine model [8, 17, 18, 20] .

    Search related documents:
    Co phrase search for related documents
    • anti inflammatory target and molecule inhibitor: 1
    • anti inflammatory target and murine model: 1
    • anti inflammatory target and novel approach: 1
    • case poor outcome and lung inflammation: 1
    • case poor outcome and poor outcome: 1, 2, 3, 4, 5, 6
    • innovative approach and novel approach: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • lung inflammation and molecule inhibitor: 1
    • lung inflammation and murine model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • lung inflammation and NF κB activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • lung inflammation and novel approach: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • lung inflammation and poor outcome: 1, 2, 3
    • molecule inhibitor and novel approach: 1
    • murine model and NF κB activation: 1, 2, 3, 4, 5, 6, 7
    • murine model and novel approach: 1, 2, 3
    • murine model and poor outcome: 1, 2, 3, 4
    • NF κB activation and novel approach: 1, 2
    • NF κB activation and poor outcome: 1
    • novel approach and poor outcome: 1